Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.74 USD
0.00 (-0.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.73 -0.01 (-1.08%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KPTI 0.74 0.00(-0.15%)
Will KPTI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPTI
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
Other News for KPTI
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (KPTI) Q2 2024 Earnings Call Transcript
Karyopharm Therapeutics: A Cautious Hold Amid Steady Performance and Pipeline Uncertainties
Karyopharm price target lowered by $3 at Baird, here's why